CJC-1295 + Ipamorelin and IGF-1 LR3 Together: What Is Known
CJC-1295 + Ipamorelin and IGF-1 LR3 taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 1 result, 2 Oct 2026).
Side by side
Showing 10 of 12 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.
| Field | CJC-1295 + Ipamorelin | IGF-1 LR3 |
|---|---|---|
| Class | GHRH + GHRP blend | IGF-1 analog |
| Also called | CJC/Ipa | LR3 |
| Category | Growth hormone | Growth hormone |
| FDA status | Not FDA approved · research blend | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times. | Prohibited by WADA (S2.3)IGF-1 and its analogues (LR3 is an IGF-1 analogue) are prohibited in S2.3, at all times. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | Ipamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 | 563 min half-life in wound fluid (versus 872 min for IGF-I)wound chamber (rat) (rat) · The American journal of physiology 1999, PMID 10198302 |
| Evidence strength | Human RCT evidence, 4 of 4Ipamorelin: International journal of colorectal disease 2014, PMID 25331030 | Human observational evidence, 3 of 4Strongest: Growth hormone & IGF research 2010, PMID 20675162 |
| Human studies we summarised | 6 human (3 randomized or controlled) of 19 summarised, across ingredients | 1 human (0 randomized or controlled) of 12 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 10 mg | 0.1 mg, 1 mg |
CJC-1295 + Ipamorelin vs IGF-1 LR3
Choosing between the two rather than combining them? The comparison lines them up field by field.
IGF-1 LR3 has no human trials
The effects of IGF-1 LR3 in humans have not been described; a case report of a vial containing a His-tagged LR3 concluded the product may be a by-product of biochemical studies rather than made for injection.[7]
In guinea pigs, LR3 enlarged some organs without stimulating overall growth.[14]
In pigs, a short LR3 infusion lowered growth hormone and the animals' own IGF-I and insulin.[15]
The blend is the GH-releasing side of the axis
In healthy adults, subcutaneous CJC-1295 produced sustained, dose-dependent rises in GH and IGF-I and was relatively well tolerated, particularly at 30 or 60 microg/kg.[5]
A PubMed search on 2 Oct 2026 for the CJC-1295 plus ipamorelin blend with IGF-1 LR3 matched 1 record, a review of performance peptides in the GH-IGF1 axis, not a trial.
Calculated from pubmed query (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))); records matched 1; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
That review's stated aim is to contrast peer-reviewed evidence with online self-administration protocols, and it describes tiers down to a complete absence of human studies.[16]
The same review lists reported adverse effects of the class, including fluid retention and dysglycaemia.[16]
Regulatory and sport status
WADA's list covers IGF-1 and its analogues.[1]
FDA lists no approved IGF-1 LR3 product.[17]
The FDA safety note on CJC-1295 lists a raised heart rate and systemic vasodilation.[18]
Common questions
Can you stack IGF-1 LR3 with CJC-1295 and ipamorelin?
No study of the combination turned up. The LR3 papers cited here are two animal studies and a case report of a product vial.[7]
Is IGF-1 LR3 safe?
The effects of LR3 in people have not been described. In pigs, a short infusion cut the animals' own GH by 23% and kept their IGF-I and insulin low.[15]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 3Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 4Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 5Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 6Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions.The American journal of physiology · 1999PMID 10198302Accessed 2 Oct 2026
- 7Detection of His-tagged Long-R³-IGF-I in a black market product.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010PMID 20675162Accessed 2 Oct 2026
- 8IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.American journal of physiology. Endocrinology and metabolism · 2025PMID 39679943Accessed 2 Oct 2026
- 9Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.Journal of Alzheimer's disease : JAD · 2025PMID 39610283Accessed 2 Oct 2026
- 10Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs.The British journal of nutrition · 2002PMID 12067429Accessed 2 Oct 2026
- 11PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab])))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 13Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.The Biochemical journal · 1993PMID 7683875Accessed 2 Oct 2026
- 14Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig.The Journal of endocrinology · 1995PMID 7561636Accessed 2 Oct 2026
- 15Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs.The Journal of endocrinology · 1997PMID 9488001Accessed 2 Oct 2026
- 16The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
- 17Drugs@FDA (openFDA) search: active ingredient "IGF-1 LR3"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 18Official web pageOfficial web page · web page
Found an error? Report a correction.